Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier Blin

Showing results (1-10 of 167) with videos related to

Pageof 17
Sort By:
Current Opinion in Neurology|June 8, 2004
The pharmacokinetics of pergolide in Parkinson's diseaseOlivier Blin
Therapie|March 26, 2005
[Chiral switch: towards a better benefit-risk ratio?]Olivier Blin
Therapie|April 3, 2021
Olivier Blin,
Therapie|April 6, 2020
Drugs and orphan diseasesOlivier Blin, Joelle Micallef
Therapie|March 12, 2020
Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseasesJoëlle Micallef, Olivier Blin
Psychologie & Neuropsychiatrie Du Vieillissement|May 19, 2005
[Biological treatment of depression in the elderly]Sylvie Bonin-Guillaume, Olivier Blin
Therapie|March 22, 2007
[Prescription switch studies: objectives, methods and limits]Vincent Pradel, Joëlle Micallef, Olivier Blin
Fundamental & Clinical Pharmacology|August 6, 2017
Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacologyJoëlle Micallef, Pierre Boutouyrie, Olivier Blin
Journal of the Neurological Sciences|June 13, 2006
Influence of visual cues on gait in Parkinson's disease: contribution to attention or sensory dependence?Jean-Philippe Azulay, Serge Mesure, Olivier Blin
Psychologie & Neuropsychiatrie Du Vieillissement|June 17, 2008
[Psychomotor retardation associated to depression differs from that of normal aging]Sylvie Bonin-Guillaume, Thierry Hasbroucq, Olivier Blin
Pageof 17

Showing results (1-10 of 167) with videos related to

Sort By:
Pageof 17
Current Opinion in Neurology|June 8, 2004
The pharmacokinetics of pergolide in Parkinson's diseaseOlivier Blin
Therapie|March 26, 2005
[Chiral switch: towards a better benefit-risk ratio?]Olivier Blin
Therapie|April 3, 2021
Olivier Blin,
Therapie|April 6, 2020
Drugs and orphan diseasesOlivier Blin, Joelle Micallef
Therapie|March 12, 2020
Orphan drug designation in Europe: A booster for the research and development of drugs in rare diseasesJoëlle Micallef, Olivier Blin
Psychologie & Neuropsychiatrie Du Vieillissement|May 19, 2005
[Biological treatment of depression in the elderly]Sylvie Bonin-Guillaume, Olivier Blin
Therapie|March 22, 2007
[Prescription switch studies: objectives, methods and limits]Vincent Pradel, Joëlle Micallef, Olivier Blin
Fundamental & Clinical Pharmacology|August 6, 2017
Pharmacology and drug development in rare diseases: the attractiveness and expertise of the French medical pharmacologyJoëlle Micallef, Pierre Boutouyrie, Olivier Blin
Journal of the Neurological Sciences|June 13, 2006
Influence of visual cues on gait in Parkinson's disease: contribution to attention or sensory dependence?Jean-Philippe Azulay, Serge Mesure, Olivier Blin
Psychologie & Neuropsychiatrie Du Vieillissement|June 17, 2008
[Psychomotor retardation associated to depression differs from that of normal aging]Sylvie Bonin-Guillaume, Thierry Hasbroucq, Olivier Blin
Pageof 17